LigaChem Biosciences Announces 170 Billion KRW Convertible Bond Issuance for R&D Funding - Potential Dilution of 3.08%

LigaChem Biosciences has decided to issue 170 billion KRW in unsecured private convertible bonds. The conversion price is 149,300 KRW per share, approximately 2.2% below the current market price of 152,600 KRW. Upon conversion, 1,138,647 new shares will be issued, representing 3.08% of outstanding shares, leading to potential dilution for existing shareholders.
The proceeds will be fully used for operating capital, specifically R&D expenses for antibody-drug conjugates and immuno-oncology drugs, allocated from 2026 to beyond 2028.
Key investors include the Korea Development Bank's Advanced Strategic Industry Fund, the largest shareholder PAN ORION Corp. Limited, and third-party financial investors, all adding credibility. The issuer holds a call option to repurchase up to 10% of bonds every three months from month 24 to 48 at a 1% annualized return.
The conversion price may be adjusted downward to a floor of 119,500 KRW based on market declines, with a 12-month reset clause.
[AI Summary]This CB issuance by LigaChem Biosciences introduces a 3.08% dilution risk for minority shareholders, but the funds are directed towards core R&D for long-term growth. Participation by credible institutional investors and the call option structure partially mitigate downside price risk. The composite score is 6, reflecting a neutral outlook.